The article describes the development of radiotherapeutic techniques in Blokhin Russian Oncological Scientific Center of Russian Academy of Medical Sciences at the end of the 20th and the beginning of the 21st centuries. Such developmental directions in radiation oncology as the development of non-conventional modes of radiation dose fractioning, the development of new radiotherapeutic techniques based on volumetric 3D dosimetric radiotherapy planning, the perfection of combined (contact plus distant) radiotherapy, the use of multidirectional radiomodifying agents, the application of radiotherapy as a part of combined and complex treatment with chemotherapy and surgery in different tumoral sensitivity to conservative treatment, are considered in the article. Immediate and long-term results achieved at the institution by the use of radiotherapy alone or as a part of combined or complex treatment in cases with certain malignant tumor localizations are described.
Download full-text PDF |
Source |
---|
Biochem Genet
January 2025
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
One in 16, 000 live births is affected by the retinal tumor RB (retinoblastoma), which is frequently found in a child's early years. Both of the RB1 alleles that have been locally mutated in the affected retina are present in 60 percent of cases. Retinoblastoma (RB) can be detected using a variety of techniques, including imaging of the brain and orbits, eye examinations under anesthesia (EUAs), and the discovery of cell-free tumor DNA in samples of aqueous humor or plasma.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
Department of Chemoradiotherapy, Ningbo No 2 Hospital, 315000 Ningbo, Zhejiang, China.
Background: Breast cancer stem cells (BCSCs) are instrumental in treatment resistance, recurrence, and metastasis. The development of breast cancer and radiation sensitivity is intimately pertinent to long non-coding RNA (lncRNA). This work is formulated to investigate how the lncRNA affects the stemness and radioresistance of BCSCs.
View Article and Find Full Text PDFPharmaceutics
December 2024
Ningbo No. 2 Hospital, Ningbo 315099, China.
The two obstacles for treating glioma are the skull and the blood brain-barrier (BBB), the first of which forms a physical shield that increases the difficulties of traditional surgery or radiotherapy, while the latter prevents antitumor drugs reaching tumor sites. To conquer these issues, we take advantage of the high penetrating ability of sonodynamic therapy (SDT), combined with a novel nanocomplex that can easily pass the BBB. Through ultrasonic polymerization, the amphiphilic peptides (CGRRGDS) were self-assembled as a spherical shell encapsulating a sonosensitizer Rose Bengal (RB) and a plant-derived compound, sulforaphane (SFN), to form the nanocomplex SFN@RB@SPM.
View Article and Find Full Text PDFPharmaceutics
December 2024
Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, Brazil.
: This study aimed to evaluate the safety and efficacy of chitosan-based bioadhesive films for facilitating the topical delivery of curcumin in skin cancer treatment, addressing the pharmacokinetic limitations associated with oral administration. : The films, which incorporated curcumin, were formulated using varying proportions of chitosan, polyvinyl alcohol, Poloxamer 407, and propylene glycol. These films were assessed for stability, drug release, in vitro skin permeation, cell viability (with and without radiotherapy), and skin irritation.
View Article and Find Full Text PDFJ Clin Med
January 2025
Tecnun, School of Engineering, University of Navarra, 20018 San Sebastian, Spain.
: The aim of this study was to analyze whether the implementation of artificial intelligence (AI), specifically the Natural Language Processing (NLP) branch developed by OpenAI, could help a thoracic multidisciplinary tumor board (MTB) make decisions if provided with all of the patient data presented to the committee and supported by accepted clinical practice guidelines. : This is a retrospective comparative study. The inclusion criteria were defined as all patients who presented at the thoracic MTB with a suspicious or first diagnosis of non-small-cell lung cancer between January 2023 and June 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!